A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
Explore related content and topics
Blog
Cancer Research and Clinical Development Since Last ASCO
Read Story
Fact Sheet
Data Monitoring Committee Unit
Due to increasing regulatory requirements, the need for quality study and patient safety data is critical as we work together to bring our clients’…
View Resource
Page
Oncology
Our in-house oncology and hematology experts make the complex, simple. PRA's global project management and clinical operations team members have an…
Read More
View all related content and resources for Oncology
Explore Insights